Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Effects of Single-dose Administration of a Novel Selective alpha2c Antagonist on Emotional and Cognitive Processing in Healthy Volunteers: an fMRI Investigation

Trial Profile

The Effects of Single-dose Administration of a Novel Selective alpha2c Antagonist on Emotional and Cognitive Processing in Healthy Volunteers: an fMRI Investigation

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jan 2019

At a glance

  • Drugs ORM 12741 (Primary)
  • Indications Alzheimer's disease
  • Focus Pharmacodynamics
  • Acronyms SNAP_MRI
  • Most Recent Events

    • 09 Jan 2019 Status changed from recruiting to completed.
    • 04 Oct 2018 Planned End Date changed from 1 Dec 2018 to 1 Mar 2019.
    • 04 Oct 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top